3 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Adrenomed AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB Adrecizumab, Placebo - Septic Shock | Phase 2 | Completed | Adrenomed AG | 301 | 2017-12-12 | 2024-02-21 |
| Adrecizumab-LPS Study Endotoxin, Placebo, Adrecizumab - Healthy Volunteers | Phase 1 | Completed | Adrenomed AG | 24 | 2017-01-04 | 2021-02-01 |
| Adrecizumab Phase 1 Trial Placebo, Adrecizumab - Healthy Volunteers | Phase 1 | Completed | Radboud University Medical Center | 24 | 2016-05-23 | 2017-03-15 |
Shock, Septic (1)
enibarcimab (3) · Endotoxins (1) · Lipopolysaccharides (1)
Netherlands (3) · Belgium (1) · France (1) · Germany (1)
Peter Pickkers, MD, PhD (2) · Jens Zimmermann, Dr. (1)
2015 (1)